Zero ad trackers.We never sell your data.Healthcare professional?Clinician Resources
Home/Rare Diseases/IgA Vasculitis with Nephritis

Kidney & Renal

IgA Vasculitis with Nephritis Clinical Trials and Treatments

Also called IgA vasculitis, Henoch-Schönlein purpura

IgA vasculitis (formerly Henoch-Schönlein purpura) is a small-vessel immune complex vasculitis characterized by predominant IgA deposition in involved organs (kidneys, skin, GI tract). The condition presents with characteristic tetrad of palpable purpura (small red spots on lower extremities and buttocks), arthritis/arthralgias, abdominal pain, and glomerulonephritis, though not all features present in every patient.

In plain words, IgA vasculitis with nephritis happens when an immune protein called IgA builds up in small blood vessels and causes swelling. This can lead to a spotty rash on the legs and joint pain, along with belly pain and kidney inflammation.

Get an email when new IgA Vasculitis with Nephritis trials open or the FDA decides. Get alerts

IgA Vasculitis with Nephritis

Where treatments stand, from ClinicalTrials.gov and FDA labels

Also 1 phase 4 study following medicines after approval.

FDA review0

No decision pending. FDA calendar

FDA-approved medicines0

No medicine's current FDA label names IgA Vasculitis with Nephritis yet.

IgA Vasculitis with Nephritis has no FDA-approved medicines, 3 open or active clinical trials (3 recruiting), and no pending FDA decision.

Labels checked October 21, 2026.Download the data

Latest for IgA Vasculitis with Nephritis

See all trialsThe week in rare disease

Each date is the day a change was posted. Open an item to see where things stand now.

More about IgA Vasculitis with Nephritis

IgA-dominant glomerulonephritis develops in approximately 40-50% of patients with systemic disease; when kidney biopsy performed in all patients, IgA deposition found in ~100%. The glomerulonephritis ranges from microscopic hematuria and mild proteinuria to rapidly progressive glomerulonephritis with crescents requiring urgent intervention.

Keep reading about IgA Vasculitis with Nephritis

About 1-5% of children progress to end-stage renal disease requiring dialysis or transplantation, while progression rates are significantly higher in adults (5-10% at 5 years). GI manifestations range from mild abdominal pain to life-threatening gastrointestinal bleeding requiring transfusion and endoscopic intervention.

Secondary complications including HUS (hemolytic uremic syndrome) and pulmonary hemorrhage occur occasionally. Elevated serum IgA level is characteristic but not diagnostic, as elevated IgA occurs in other conditions. Most children achieve complete remission of systemic disease, though renal involvement duration and severity predict persistent or progressive renal disease.

What are the symptoms of IgA Vasculitis with Nephritis?

These are common symptoms of IgA Vasculitis with Nephritis, and how strong they are varies from person to person.

  • Palpable purpura on lower extremities and buttocks
  • Arthritis and arthralgias
  • Glomerulonephritis with hematuria and proteinuria
  • Abdominal pain and GI bleeding
  • Renal dysfunction and hypertension
  • Elevated serum IgA levels

Who gets IgA Vasculitis with Nephritis?

Most common in children ages 3-10 years with peak incidence 4-6 years, though can occur at any age from infancy to elderly. Slight male predominance at approximately 1.5:1 to 2:1 male-to-female ratio. Significantly higher prevalence in East Asian populations (particularly Japan, Korea, China) and Mediterranean populations compared to Northern European and African populations.

Estimated prevalence varies 5-10 fold between populations. Seasonal variation with increased incidence in autumn and winter correlating with upper respiratory infections. Often preceded by upper respiratory infection or other infectious trigger 1-2 weeks prior to symptom onset. Recurrent or persistent hematuria occurs in approximately 40% of patients even after systemic disease resolution.

Next steps: find trials you might fitsee what is being testedget help payingget alerts

Side effects people have reported to the FDA

Side effects people have reported to the FDA

Real-world side effect reports from the FDA Adverse Event Reporting System (FAERS). Includes both FDA-approved drugs and investigational therapies from active clinical trials. Click any drug to see what patients reported.

Loading side effect data...

Diagnosis and genetic testing

Genetic testing for IgA Vasculitis with Nephritis

Genetic testing can confirm a diagnosis, guide treatment decisions, and identify family members who may be at risk.

Finding labs...

Trusted IgA Vasculitis with Nephritis resources

Reputable organizations and medical references for learning more about IgA Vasculitis with Nephritis, including disease registries, foundation resources, and clinical guidelines.

Active clinical trials for IgA Vasculitis with Nephritis

Use this IgA Vasculitis with Nephritis clinical trial finder to see the 3 studies recruiting patients in the United States and worldwide, with eligibility criteria in plain English. All of them test a treatment. Every trial comes from ClinicalTrials.gov.

Jump to the trial list, the site map or the pipeline timeline.

Note: Trial recruitment statuses on ClinicalTrials.gov may not immediately reflect recent FDA decisions, sponsor announcements, or enrollment changes. Always confirm a trial's current status directly with the study coordinator before making plans.

3 active trials worldwide
Filter:
Sort:
RecruitingTreatment trialPhase 3Updated a few months agoNCT07024563

Study of Ravulizumab in Pediatric Participants With Primary IgAN

Intervention: Ravulizumab

Sponsor: Alexion Pharmaceuticals, Inc.

The primary objectives of this study are to characterize ravulizumab pharmacokinetics (PK) and pharmacodynamics (PD), and to evaluate safety and efficacy following ravulizumab IV dosing in pediatric participants with IgAN or IgAVN.

Ages 2 Years to 18 Years
Started Jun 2025Updated 3 months agoEst. Nov 2028 (~2 years)
RecruitingTreatment trialPhase 2No updates in a whileNCT05003986

Study of Sparsentan Treatment in Pediatrics With Proteinuric Glomerular Diseases

Intervention: Sparsentan, Sparsentan, Sparsentan

Sponsor: Travere Therapeutics, Inc.

To evaluate the safety, efficacy and tolerability of sparsentan oral suspension and tablets, and assess changes in proteinuria after once-daily dosing over 108 weeks.

Ages 1 Year to 17 Years
Started Aug 2021Updated 6 months agoEst. Mar 2027 (~3 months)
RecruitingTreatment trialPhase 4Hasn't posted an update in over a yearNCT06676384

Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve the Slope of Estimated Glomerular Filtration Rate at Two Years When Compared to Standard of Care Alone in South-Asian Kidney Biopsy-proven Adult (≥18 Years) Primary IgA Nephropathy?

Intervention: Oral prednisolone and SoC, Gut-directed budesonide and SoC, Mycophenolate mofetil (MMF) and SoC, Hydroxychloroquine and SoC, Non-steroidal mineralocorticoid receptor antagonist and SoC, SoC defined as maximal labelled or tolerated dose of angiotensin-converting enzyme inhibitor/ angiotensin receptor blocker (ACEi/ARB) & steady dose of sodium-glucose cotransporter-2 inhibitor (SGLT2i)

Sponsor: Christian Medical College, Vellore, India

Global Burden of Diseases ranks chronic kidney disease (CKD) as the 12th leading cause of death, with an estimated 20% increase from 2010 to 2019. India is the most populous country in South Asia, with one-fourth of the global population. CKD prevalence has reached epidemic propo...

Ages 18 Years to 65 Years
Started Feb 2025Updated 1 year agoEst. Aug 2029 (~2y 9m)
Find IgA Vasculitis with Nephritis trials near you, ranked by distance →
Active trial locations22 cities in the US
A study site. Select it to see its trials and get directions. Several sites close together. Select the number to zoom in.
+14 more

Trial Pipeline

Aug 2021 to Apr 2030
2022
2024
2026
2028
2030
now
Phase 2
Phase 3
Phase 4
RecruitingNot yet recruitingDelayed startTodayHover a bar for trial details

Read more about IgA Vasculitis with Nephritis trials

Need help understanding these trials?
Answers with sources, in plain English
Start withor ask
Run an IgA Vasculitis with Nephritis foundation or patient group?
You can put this live trial list on your own website. It updates itself, and it's free.
Get the embed code →

Data from ClinicalTrials.gov, U.S. National Library of Medicine.
Always talk to your doctor before considering a clinical trial.

IgA Vasculitis with Nephritis patient communities

Facebook groups, Reddit communities and YouTube channels where IgA Vasculitis with Nephritis patients, caregivers and advocacy groups talk.

Companies developing IgA Vasculitis with Nephritis treatments

Drugmakers that list IgA Vasculitis with Nephritis in their rare disease portfolio, 2 in all.

Questions people ask about IgA Vasculitis with Nephritis